3 August 2022
Ropes & Gray Advises IDRx in Licensing Agreements with Merck KGaA and Blueprint Medicines in Connection with $122 Million Series A Financing
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Abigail Gregor Lead | Ropes & Gray | Partner | life sciences | Not stated |
| Daniel Freshman | Ropes & Gray | Associate | Not stated | Not stated |
| Joe Muller | Ropes & Gray | Associate | Not stated | Not stated |
| Mallory Ursul | Ropes & Gray | Associate | Not stated | Not stated |
| David Saltzman | Ropes & Gray | Partner | tax | Not stated |
| David Peloquin | Ropes & Gray | Partner | health care | Not stated |
| Ryan Murphey | Ropes & Gray | Not stated | IP transactions | Not stated |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 122m ($122 million)
- What the figure measures
- Total transaction value
- Client
- IDRxIssuer
- Counterparties
- Andreessen Horowitz (Investor)
Casdin Capital (Investor)
Nextech Invest (Investor)
Forge Life Sciences Partners (Investor)
Merck KGaA (Other)
Blueprint Medicines (Other)